We potentially have 273,000 patients in MDR2 and MDR3. Conservatively I think we can capture 50% of the MDR3 market (13,500) and 10% of the MDR2 segment (24,600). With 38,100 patients that would put us at $204m in earnings. More than enough to fully explore every single indication at the same time.

Of course then there's also the rest of the world left to sell too.